Ultime notizie per Celularity (NASDAQ:CELU) Azioni

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) announced its unaudited interim financial results on Thursday for the third quarter ending Sept. 30, 2024.
&#8220;Decibel has been very deliberate about reducing our current liabilities, by ~5mm this quarter," CEO Benjamin Sze said.&nbsp;"Maintaining discipline over time will result in a stronger balance sheet.&nbsp; This marks the last quarter where our primary focus is on Canadian domestic recreational sales. While we continue to integrate AgMedica into our portfolio, it is encouraging to see significant demand internationally for Decibel flower.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40369534/decibel-cannabis-reports-22-yoy-decrease-in-q2-net-revenue-plans-to-benefit-with-new-product-lau">Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q3 Financial Highlights</h3>
<ul>
<li>Net revenue totaled CA$24.1 million ($17.2 million), representing a 9% increase sequentially, but a 12% decrease year-over-year.</li>
<li>Gross profit before fair value adjustments was CA$12.7 million, compared to roughly CA$12 million in the prior year's period.</li>
<li>Gross margin before fair value adjustments reached 53% in the third quarter, up from 44% in the prior year's period, reflecting improved operational efficiency.</li>
<li>Adjusted EBITDA was positive at CA$5.1 million, representing a 31% increase from the previous quarter but a 21% decrease year over year.</li>
<li>Net loss and comprehensive loss amounted to CA$585 000, compared to a net income and comprehensive income of CA$413 000.</li>
<li>Generated positive free cash flow of $1.8 million, up 75% year-over-year.</li>
</ul>
The company said that it's seeing significant demand for its flower internationally as it continues to integrate AgMedica.
Decibel <a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance">closed the acquisition</a> of AgMedica Bioscience Ltd. in October. The transaction was arranged through an agreement with Callisto Capital Corp. and was made in exchange for a $6.3 million unsecured convertible debenture.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40577591/decibels-10m-strategy-how-it-could-enhance-your-canadian-cannabis-portfolio">Decibel&#8217;s $10M Strategy: How It Could Enhance Your Canadian Cannabis Portfolio</a></li>
</ul>
<h3 class="wp-block-heading">DBCCF Price Action</h3>
Decibel's shares traded 5.54% higher at $0.0495 per share after the market close on Thursday afternoon.

Cannabis

Earnings

News

DBCCF

TSXV:DB

Canadian Cannabis Co. Decibel Reports 12% YoY Drop In Q3 Revenue But Increases Gross Margin To 53%

Wells Fargo analyst Joe Quatrochi initiates coverage on Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Overweight rating and announces Price Target of $350.

Price Target

Initiation

Analyst Ratings

CDNS

Wells Fargo Initiates Coverage On Cadence Design Sys with Overweight Rating, Announces Price Target of $350

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846ee56ee7bf6000154d12e/tom-nikic">Needham analyst Tom Nikic</a> initiated coverage on NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy rating and announced a price target of $84. Nike shares closed at $75.10 on Thursday. See how other analysts view this stock.</li>
<li>JP Morgan analyst Bennett Moore initiated coverage on Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) with an Overweight rating and announced a price target of $220. Carpenter Tech shares closed at $180.71 on Thursday. <a href="https://www.benzinga.com/quote/CRS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities analyst Tyler DuPont initiated coverage on Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) with a Buy rating and announced a price target of $40. Kyndryl shares closed at $32.49 on Thursday. <a href="https://www.benzinga.com/quote/KD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst John Hodulik initiated coverage on Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Neutral rating and announced a price target of $73. Roku shares closed at $68.68 on Thursday. <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo analyst Joe Quatrochi initiated coverage on Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with an Overweight rating and announced a price target of $155. ARM shares closed at $133.14 on Thursday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NKE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246-1024x544.png" alt="" class="wp-image-660970" style="width:666px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246.png 1255w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ROKU

This Nike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

HUDA

Hudson Acquisition I Corp Signs Definitive Business Combination Agreement With Aiways Europe; Transaction Represents Pre-Combination Equity Valuation Of $410M For Airways Europe, Subject To Adjustment

Wells Fargo analyst Joe Quatrochi initiates coverage on MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Equal-Weight rating and announces Price Target of $14.

Wells Fargo Initiates Coverage On MaxLinear with Equal-Weight Rating, Announces Price Target of $14

Wells Fargo analyst Gary Mobley initiates coverage on Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Equal-Weight rating and announces Price Target of $220.

Wells Fargo Initiates Coverage On Analog Devices with Equal-Weight Rating, Announces Price Target of $220

The looming threat of the removal of the clean energy <a href="https://www.benzinga.com/news/24/09/40752747/trump-wants-to-end-ev-tax-credits-but-yellen-warns-of-higher-bills-lost-jobs-and-chinas-gain">tax credit has rattled some</a>, but JPMorgan analyst Bill Peterson says EVgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is set up for success.
"EVGO sees improving affordability of a larger variety of vehicles as being the primary driver of mass EV adoption," Peterson says, adding, "new EV sales would need to decline by 40% to impact the company's trajectory, which is unlikely to happen."
Even if the credit is removed, Peterson forecasts that "16% US [battery electric vehicle] penetration by 2030" is still achievable.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41899963/evgo-q3-sales-surge-92-as-charging-revenues-and-customer-growth-drive-performance-stock-jumps">EVgo Q3 Sales Surge 92% As Charging Revenues And Customer Growth Drive Performance; Stock Jumps</a>
"While it has been reported that Trump's transition team intends to remove the 30D tax credit, there could be alternative ways that the administration changes it," he said, suggesting modifications like domestic content requirements or changes to MSRP and income eligibility.
<h2 class="wp-block-heading">EVgo&#8217;s Strategic Footprint Protects Growth</h2>
EVgo's strategic positioning in Republican-led states like Texas, Florida, and Arizona also sets it up for success, especially considering that these regions don't have the same emissions standards as California. Peterson added, "EVGO is relatively shielded from new EV sales growth, given it continues to drive momentum from a stable/growing EV fleet," while pointing to opportunities in autonomous and rideshare markets as potential additional growth drivers.
EVgo's confidence surrounding its Department of Energy (DOE) loan is "reaffirmed.&#8221; CEO Badar Khan called the process "de-risked" and nearing closure. Peterson feels the loan will allow EVgo to revise its EBITDA targets upward, stating, "We feel confident that EVGO will revise its EBITDA targets higher upon receiving the loan and disclose its planned build schedule through 2030."
<h2 class="wp-block-heading">Funding Concerns Seem Overblown</h2>
Despite some investor concerns about a potential clawback of funds, Peterson remains unconcerned, stating, "The government is unlikely to renegotiate its finalized contracts with US companies, especially if building charging infrastructure stimulates further EV demand and improves US competitiveness with China." 
Peterson also noted that, despite concerns over the loss of the 30C tax credit, "EVGO's business model is not reliant on highway sites."
<h2 class="wp-block-heading">EVGO Stock: A Bullish Trajectory</h2>
With 10,000 viable sites and further expansion on the horizon, EVgo's trajectory is still bullish. Peterson concluded that, "The opportunities for growth continue to increase with EV adoption," making EVgo a strong contender in the EV infrastructure race.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41926301/sustainable-investment-under-trump-performance-matters-far-more-than-politics-jpmorgan-analyst-says">Sustainable Investment Under Trump: &#8216;Performance Matters Far More Than Politics,&#8217; JPMorgan Analyst Says</a></li>
</ul>

Analyst Color

Long Ideas

Tech

EVGO

EVgo Powers On Despite Trump Shake-Up: Analyst Projects 16% US Battery EV Penetration By 2030

Wells Fargo analyst Joe Quatrochi initiates coverage on NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight rating and announces Price Target of $250.

NXPI

Wells Fargo Initiates Coverage On NXP Semiconductors with Overweight Rating, Announces Price Target of $250

WIIM

VRPX

Virpax shares are trading higher after the company announced results from the swine model dose range finding study for Probudur.

Evotec shares are trading lower after Halozyme withdrew its €2 billion proposal to acquire the company.

JTAI

Jet.AI shares are trading higher after the company announced a fleet purchase agreement with Textron Aviation to purchase three Cessna Citation CJ3 Gen2 aircraft.

After Warren Buffett's conglomerate Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) declared its <a href="https://www.berkshirehathaway.com/qtrly/3rdqtr24.pdf">third-quarter results</a> in early November, investors have been curious as to why he sitting on nearly $325 billion in cash and equivalents.
What Happened: Analysts have been speculating an array of reasons for the world's most famous value investor to be holding such a huge pile of cash. It could be for an acquisition plan, a buyback<a href="https://www.benzinga.com/markets/24/11/41869558/warren-buffetts-apple-stake-reduction-spurs-97b-cash-surge-analysts-speculate-this-could-be-the-reas?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=real_estate"> plan in case of a succession,</a> or an expectation of a market fall.
Also read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42084722/warren-buffett-destroy[%E2%80%A6]-not-investing-in-bitcoin-says-microstrategys-michael-saylor">Warren Buffett &#8216;Destroying $3B A Month&#8217; Of Berkshire Capital By Not Investing In Bitcoin, Says MicroStrategy&#8217;s Michael Saylor</a>
The stock markets have been trading higher than their pre-election levels with a looming threat of a possible pause in the interest rate cuts. This has led analysts to wonder if Berkshire is avoiding investing because he cannot find any value in the markets at the current level.
&#8220;What some describe as a hot stock market, Warren Buffett would describe as overpriced,&#8221; Cathy Seifert, a director at CFRA Research <a href="https://fortune.com/2024/11/22/warren-buffett-berkshire-pool-dominos-nvidia-sidelines-hot-stock-market/">told</a> Fortune. 
Buffet&#8217;s current stance on the cash "reflects a fundamental skepticism about the sustainability of current market valuations, the sustainability of the Trump trade, combined with the fact that they're not seeing a lot of acquisition targets that are appealing to them,&#8221; she said.
The 94-year-old Buffet will be succeeded by Greg Abel to run Berkshire. "The unfortunate actuarial reality is, at some point in time, you have a change in senior management, and I suspect that they want to have a lot of cash to buy back Berkshire Hathaway stock," said Meyer Shields, managing director at Keefe, Bruyette &amp; Woods to <a href="https://fortune.com/2024/11/22/warren-buffett-berkshire-pool-dominos-nvidia-sidelines-hot-stock-market/">Fortune</a>. He implied that freely available cash can be utilized in case of a sell-off to benefit the shareholders
On the other hand, MicroStrategy Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) co-founder, Michael Saylor has said that <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42084722/warren-buffett-destroy[%E2%80%A6]-not-investing-in-bitcoin-says-microstrategys-michael-saylor">Buffett is destroying billions of dollars</a> in capital by not utilizing the cash at their disposal to invest in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
"That $320 billion.. that is destroying $32 billion a year. They are destroying $3 billion a month in capital because they're generating a 3% after-tax yield at best, and the cost of capital is 15%. So take 12% negative real yield," Saylor said.
Also read: <a href="https://www.benzinga.com/24/11/42132644/reddit-falls-7-in-afterhours-as-advance-plans-stake-sale-technicals-show-strong-support-but-selling-pressure-persists-at-overbought-levels">Reddit Tumbles 7% In Premarket Amid Advance&#8217;s Stake Sale Announcement: Technicals Show Strong Support, But Selling Pressure Persists At Overbought Levels</a>
Why It Matters: By holding cash and equivalents Berkshire could be making only &#8220;3% after-tax yield at best, and the cost of capital is 15%. So take 12% negative real yield,&#8221; said MicroStrategy&#8217;s Saylor
While analysts speculate various reasons, Saylor in a podcast with Patrick Bet-David made a case for Buffet to invest in Bitcoin. "I'd want to bet you that if I had an hour alone with Buffett in a calm environment, I'd walk out and he would say this Bitcoin thing is a pretty good idea."
Saylor was optimistic that Buffett would have wanted to buy Bitcoin after the interaction and would come out saying that the late Charlie Munger would have liked the idea.
Read next: <a href="https://www.benzinga.com/24/11/42134031/markets-got-it-wrong-after-elections-prospects-of-tariffs-not-good-for-equities-vs-dollar-says-ex-goldman-sachs-analyst">Markets Misread Trump Win, Says Ex-Goldman Sachs Analyst: &#8216;Prospects Of Tariffs Not Good For Equities&#8217;</a>
Image via Shutterstock

Equities

General

$BTC

MSTR

As MSTR's Michael Saylor Says Warren Buffett Is 'Destroying' Berkshire Capital, Analyst Suggests 'Overpriced…Hot Stock Market' Could Be The Reason Oracle Of Omaha Is Sitting On $325B Cash

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584847d9ee7bf6000154d223/deane-dray">RBC Capital analyst Deane Dray</a> upgraded the rating for Flowserve Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) from Sector Perform to Outperform and announced a $69 price target. Flowserve shares closed at $60.05 on Thursday. See how other analysts view this stock.</li>
<li>Keybanc analyst Jeffrey Hammond upgraded RBC Bearings Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) from Sector Weight to Overweight and announced a $375 price target. RBC Bearings shares closed at $324.45 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird analyst Shrenik Kothari upgraded the rating for Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from Neutral to Outperform and raised the price target from $95 to $135. Elastic shares closed at $94.13 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners analyst David Risinger upgraded the rating for AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Market Perform to Outperform and announced a $206 price target. AbbVie shares closed at $171.73 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Seaport Global analyst Glenn Chin upgraded Sonic Automotive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) from Neutral to Buy and announced a $74 price target. Sonic Automotive shares closed at $63.20 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ESTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-1024x559.png" alt="" class="wp-image-660959" style="width:657px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245.png 1205w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november"> </a>
<ul>
<li><a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a></li>
</ul>

Upgrades

ABBV

ESTC

This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) shares are trading higher premarket on Friday after the company disclosed that its subsidiary, Beneficient Company Holdings, L.P., has completed a transaction where approximately $35 million of its preferred equity was redesignated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42133708/beneficient-consummates-transaction-to-increase-permanent-equity-by-35-million" rel="noreferrer noopener">as non-redeemable</a>.
This transaction resulted in the addition of approximately $35 million in permanent equity to the balance sheet.
Consequently, the company now believes it meets the Nasdaq Minimum Stockholders&#8217; Equity Requirement, with stockholders&#8217; equity of at least $2.5 million. However, Nasdaq&#8217;s final determination will confirm the company&#8217;s compliance.
Beneficient also announced the appointment of Karen J. Wendel as an independent member of its Board of <a target="_blank" href="https://www.benzinga.com//node/42133707" rel="noreferrer noopener">Directors as of November 21.</a>
Apart from this, Beneficient, through its subsidiary Beneficient Fiduciary Financial, L.L.C., provided an update to the State of Kansas Joint Committee on<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42126842/beneficient-reports-to-kansas-legislative-committee-on-its-positive-developments-and-the-digital-t" rel="noreferrer noopener"> Fiduciary Financial Institutions Oversight</a>.
The update highlighted the company&#8217;s business operations, digital innovations in the alternative asset industry, and its contributions to economic development in Kansas communities.
During its testimony, Beneficient executives reviewed the company&#8217;s fiscal second-quarter results for the period ending September 30, 2024, marking the second consecutive quarter of positive diluted earnings per share for its common shareholders.
The company highlighted advancements in its financial industry-focused business, including new technology innovations, an authorization from its board to complete up to $5 billion in fiduciary financings, and a transaction that reclassified certain preferred equity, increasing Beneficient&#8217;s permanent equity by $126 million.
The testimony also emphasized progress on key projects funded primarily by proceeds generated under the Kansas Technology-Enabled Fiduciary Financial Institutions (TEFFI) Act.
Price Action: BENF shares are up 18.2% at $1.04 premarket at the last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42134782" target="_blank" rel="noreferrer noopener">After Plunging 16%, MicroStrategy Makes Modest Recovery In Friday Pre-Market: Is There Still Hope For A $100K BTC Effect?</a></li>
</ul>

Large Cap

Legal

Movers

BENF

Beneficient Adds $35 Million In Permanent Equity, Aiming For Nasdaq Compliance

BTAI

BioXcel Therapeutics shares are trading lower after the company announced a public offering valued at $7 million consisting of shares and warrants.

Offerings

INDP

Indaptus Therapeutics Announces $2.135M Registered Direct Offering And Private Placement, Issuing Shares And Warrants At $1.175 Per Unit, With Closing Expected November 25, 2024

Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment

Biotech

APVO

Aptevo Provided Details About Portfolio On Cancer Immunotherapy

HALO

Halozyme Therapeutics shares are trading higher after the company announced it withdrew plans to acquire Evotec.

Halozyme Withdraws €2B Proposal To Acquire Evotec After Evotec Declines Engagement, Citing Commitment To Independence; Halozyme Reaffirms 2024 Guidance And Strategic Growth Targets

Raymond James analyst Andrew Marok reiterates Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Strong Buy and maintains $60 price target.

Reiteration

RBLX

Raymond James Reiterates Strong Buy on Roblox, Maintains $60 Price Target

Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His d...

Celularity Board Member Marc Mazur Announces Resignation

Celularity receives Nasdaq notice regarding late Form 10-Q filing

The latest announcement is out from Celularity (CELU). Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, f...

Celularity Announces Board Changes and New Indemnification Agreement

Celularity acquires Rebound product from Sequence Lifescience

Celularity receives Nasdaq notice, intends to file appeal

Celularity (CELU) issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by re...

Celularity to submit 510(k) notification for Tendon Wrap in early 2025

Celularity (CELU) has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding C...

Celularity files amended compliance plan with Nasdaq Hearings Panel

Celularity (CELU) announced that the Nasdaq Listing Qualifications Hearings Panel has cancelled the hearing regarding Celularity's non-compliance w...

Celularity resolves Nasdaq listing compliance issue

Celularity announces resolution of Nasdaq listing compliance matter

Celularity (CELU) announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a stem cell and regenerative medicine...

Celularity strategic partner announces stem cell, regenerative medicine center

CELU

CELUW

Press Releases

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Management

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Provides Corporate Update

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Comments

Celularity

Notizie

Ultime notizie per Celularity (NASDAQ:CELU) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO